Note: In these datasets, a person is defined as up to date if they have received at least one dose of an updated COVID-19 vaccine. The Centers for Disease Control and Prevention (CDC) recommends that certain groups, including adults ages 65 years and older, receive additional doses.

On 6/16/2023 CDPH replaced the booster measures with a new “Up to Date” measure based on CDC’s new recommendations, replacing the primary series, boosted, and bivalent booster metrics The definition of “primary series complete” has not changed and is based on previous recommendations that CDC has since simplified. A person cannot complete their primary series with a single dose of an updated vaccine. Whereas the booster measures were calculated using the eligible population as the denominator, the new up to date measure uses the total estimated population. Please note that the rates for some groups may change since the up to date measure is calculated differently than the previous booster and bivalent measures.

This data is from the same source as the Vaccine Progress Dashboard at https://covid19.ca.gov/vaccination-progress-data/ which summarizes vaccination data at the county level by county of residence. Where county of residence was not reported in a vaccination record, the county of provider that vaccinated the resident is included. This applies to less than 1% of vaccination records. The sum of county-level vaccinations does not equal statewide total vaccinations due to out-of-state residents vaccinated in California.

These data do not include doses administered by the following federal agencies who received vaccine allocated directly from CDC: Indian Health Service, Veterans Health Administration, Department of Defense, and the Federal Bureau of Prisons.

Totals for the Vaccine Progress Dashboard and this dataset may not match, as the Dashboard totals doses by Report Date and this dataset totals doses by Administration Date. Dose numbers may also change for a particular Administration Date as data is updated.

Previous updates:

• On March 3, 2023, with the release of HPI 3.0 in 2022, the previous equity scores have been updated to reflect more recent community survey information. This change represents an improvement to the way CDPH monitors health equity by using the latest and most accurate community data available. The HPI uses a collection of data sources and indicators to calculate a measure of community conditions ranging from the most to the least healthy based on economic, housing, and environmental measures.

• Starting on July 13, 2022, the denominator for calculating vaccine coverage has been changed from age 5+ to all ages to reflect new vaccine eligibility criteria. Previously the denominator was changed from age 16+ to age 12+ on May 18, 2021, then changed from age 12+ to age 5+ on November 10, 2021, to reflect previous changes in vaccine eligibility criteria. The previous datasets based on age 16+ and age 5+ denominators have been uploaded as archived tables.

• Starting on May 29, 2021 the methodology for calculating on-hand inventory in the shipped/delivered/on-hand dataset has changed. Please see the accompanying data dictionary for details. In addition, this dataset is now down to the ZIP code level.

The number of COVID-19 vaccination doses administered in the World rose to 9976338443 as of Jan 27 2022. This dataset includes a chart with historical data for World Coronavirus Vaccination Total.

As of January 18, 2023, Portugal had the highest COVID-19 vaccination rate in Europe having administered 272.78 doses per 100 people in the country, while Malta had administered 258.49 doses per 100. The UK was the first country in Europe to approve the Pfizer/BioNTech vaccine for widespread use and began inoculations on December 8, 2020, and so far have administered 224.04 doses per 100. At the latest data, Belgium had carried out 253.89 doses of vaccines per 100 population. Russia became the first country in the world to authorize a vaccine - named Sputnik V - for use in the fight against COVID-19 in August 2020. As of August 4, 2022, Russia had administered 127.3 doses per 100 people in the country.

The seven-day rate of cases across Europe shows an ongoing perspective of which countries are worst affected by the virus relative to their population. For further information about the coronavirus pandemic, please visit our dedicated Facts and Figures page.

The average for 2022 based on 187 countries was 85 percent. The highest value was in Antigua and Barbuda: 99 percent and the lowest value was in North Korea: 0 percent. The indicator is available from 1980 to 2022. Below is a chart for all countries where data are available.

As of June 7, 2022, China had administered almost 3.4 billion doses of COVID-19 vaccines, representing around 28 percent of the 11.9 billion doses administered worldwide.

Vaccination rate

China has one of the highest COVID-19 vaccination rates in the world. Nevertheless, the situation varies substantially between age groups. Unlike many other regions such as Japan and western Europe, the Chinese elderly population has a lower vaccination rate than the younger generations. As of March 2022, only around half of people aged above 80 were fully vaccinated in the country, while less than 20 percent had their booster vaccinations.

The insufficient vaccination rate among the most vulnerable group of the society partially explains China’s “Zero COVID” strategy, as many fear that the healthcare service will not be able to cope with the spread of COVID-19.

Chinese vaccines

As a major partner and stakeholder of BioNTech, the German developer of Comirnaty, Chinese pharmaceutical firm Fosun Pharma secured 100 million doses of mRNA COVID-19 vaccines in the early days of the pandemic. Nevertheless, no mRNA vaccine received approval from the Chinese regulator and the majority of the doses secured by Fosun remained undelivered.

Sinovac and Sinopharm’s vaccines, the two most common COVID-19 vaccines in China, are both inactivated whole virus vaccines, which stimulate immune responses with killed SARS-CoV-2 virus. Despite having many advantages, they are significantly less effective than mRNA vaccines in preventing symptomatic illness and are especially problematic when encountering the latest Omicron variant of SARS-CoV-2.

Denmark DK: Immunization: Measles: % of Children Aged 12-23 Months data was reported at 94.000 % in 2016. This records an increase from the previous number of 91.000 % for 2015. Denmark DK: Immunization: Measles: % of Children Aged 12-23 Months data is updated yearly, averaging 88.500 % from Dec 1987 (Median) to 2016, with 30 observations. The data reached an all-time high of 99.000 % in 2000 and a record low of 72.000 % in 1988. Denmark DK: Immunization: Measles: % of Children Aged 12-23 Months data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Denmark – Table DK.World Bank: Health Statistics. Child immunization, measles, measures the percentage of children ages 12-23 months who received the measles vaccination before 12 months or at any time before the survey. A child is considered adequately immunized against measles after receiving one dose of vaccine.; ; WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/).; Weighted average;

France FR: Immunization: Measles: % of Children Aged 12-23 Months data was reported at 90.000 % in 2017. This stayed constant from the previous number of 90.000 % for 2016. France FR: Immunization: Measles: % of Children Aged 12-23 Months data is updated yearly, averaging 84.000 % from Dec 1983 (Median) to 2017, with 35 observations. The data reached an all-time high of 91.000 % in 2015 and a record low of 15.000 % in 1983. France FR: Immunization: Measles: % of Children Aged 12-23 Months data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s France – Table FR.World Bank.WDI: Health Statistics. Child immunization, measles, measures the percentage of children ages 12-23 months who received the measles vaccination before 12 months or at any time before the survey. A child is considered adequately immunized against measles after receiving one dose of vaccine.; ; WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/).; Weighted average;

Weighted percentage crude (ignoring age at vaccination or interval between doses) and valid (respecting the schedule) vaccination coverage for the basic EPI vaccines, children aged 12–23 months, MICS/NICS 2016–17.

In line with encountering the world with the emergence of vaccine-resistance variants of SARS-CoV-2, 15,669,529 samples that received COVID-19 vaccines until April 2023 were investigated as two doses in the first phase and booster vaccinations in the second phase. The analysis shows that D614G and P681 mutations occurred in both phases. The E484 and Y655 mutations significantly emerged during the second phase. The 762-889 and 254-381 regions are revealed as conserved parts and could be considered in vaccine design. The Kruskal–Wallis test revealed a significant reduction in single mutations between populations with 20%–50% and those with 70%–100% vaccination coverage (p=0.017). The Mann–Whitney U test proposes a link between vaccination and suppression of viral mutation rates. Dynamic modeling suggests that key mutations have facilitated the virus’ evolution and immune escape. The study’s findings are crucial for understanding virus genome mutations, especially E614 and P681 in Delta and E484 and H655 in Omicron. This highlights the need to adjust strategies and strengthen global efforts in combating the pandemic.

Jordan JO: Immunization: Measles: % of Children Aged 12-23 Months data was reported at 96.000 % in 2016. This records an increase from the previous number of 94.000 % for 2015. Jordan JO: Immunization: Measles: % of Children Aged 12-23 Months data is updated yearly, averaging 94.000 % from Dec 1980 (Median) to 2016, with 37 observations. The data reached an all-time high of 99.000 % in 2006 and a record low of 29.000 % in 1980. Jordan JO: Immunization: Measles: % of Children Aged 12-23 Months data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Jordan – Table JO.World Bank: Health Statistics. Child immunization, measles, measures the percentage of children ages 12-23 months who received the measles vaccination before 12 months or at any time before the survey. A child is considered adequately immunized against measles after receiving one dose of vaccine.; ; WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/).; Weighted average;

Immunization, BCG (% of one-year-old children) in Afghanistan was reported at 68 % in 2023, according to the World Bank collection of development indicators, compiled from officially recognized sources. Afghanistan - Immunization, BCG (% of one-year-old children) - actual values, historical data, forecasts and projections were sourced from the World Bank on March of 2025.

San Marino Immunization: Measles: % of Children Aged 12-23 Months data was reported at 82.000 % in 2017. This stayed constant from the previous number of 82.000 % for 2016. San Marino Immunization: Measles: % of Children Aged 12-23 Months data is updated yearly, averaging 94.000 % from Dec 1991 (Median) to 2017, with 27 observations. The data reached an all-time high of 99.000 % in 2000 and a record low of 81.000 % in 2014. San Marino Immunization: Measles: % of Children Aged 12-23 Months data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s San Marino – Table SM.World Bank: Health Statistics. Child immunization, measles, measures the percentage of children ages 12-23 months who received the measles vaccination before 12 months or at any time before the survey. A child is considered adequately immunized against measles after receiving one dose of vaccine.; ; WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/).; Weighted average;

Constant efforts to prevent infections by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are actively carried out around the world. Several vaccines are currently approved for emergency use in the population, while ongoing studies continue to provide information on their safety and effectiveness. CoronaVac is an inactivated SARS-CoV-2 vaccine with a good safety and immunogenicity profile as seen in phase 1, 2, and 3 clinical trials around the world, with an effectiveness of 65.9% for symptomatic cases. Although vaccination reduces the risk of disease, infections can still occur during or after completion of the vaccination schedule (breakthrough cases). This report describes the clinical and immunological profile of vaccine breakthrough cases reported in a clinical trial in progress in Chile that is evaluating the safety, immunogenicity, and efficacy of two vaccination schedules of CoronaVac (clinicaltrials.gov NCT04651790). Out of the 2,263 fully vaccinated subjects, at end of June 2021, 45 have reported symptomatic SARS-CoV-2 infection 14 or more days after the second dose (1.99% of fully vaccinated subjects). Of the 45 breakthrough cases, 96% developed mild disease; one case developed a moderate disease; and one developed a severe disease and required mechanical ventilation. Both cases that developed moderate and severe disease were adults over 60 years old and presented comorbidities. The immune response before and after SARS-CoV-2 infection was analyzed in nine vaccine breakthrough cases, revealing that six of them exhibited circulating anti-S1-RBD IgG antibodies with neutralizing capacities after immunization, which showed a significant increase 2 and 4 weeks after symptoms onset. Two cases exhibited low circulating anti-S1-RBD IgG and almost non-existing neutralizing capacity after either vaccination or infection, although they developed a mild disease. An increase in the number of interferon-γ-secreting T cells specific for SARS-CoV-2 was detected 2 weeks after the second dose in seven cases and after symptoms onset. In conclusion, breakthrough cases were mostly mild and did not necessarily correlate with a lack of vaccine-induced immunity, suggesting that other factors, to be defined in future studies, could lead to symptomatic infection after vaccination with CoronaVac.

As of March 15, 2023, Seychelles was the African country with the highest coronavirus (COVID-19) vaccination rate, with around 205 doses administered per 100 individuals. Mauritius and Rwanda followed with 201 and 190 doses per 100 people, respectively. Ranking fourth, Morocco had a vaccination rate of approximately 148 doses per 100 people, registering the third-highest number of inoculations after Egypt and Nigeria. In South Africa, the most affected country on the continent, the vaccination rate instead reached around 64 per 100 population.

How did Africa obtain the vaccines?

Vaccines in Africa were obtained in different ways. African nations both purchased new doses and received them from other countries. At the beginning of the vaccination campaigns, donations came from all over the world, such as China, the United Arab Emirates, India, and Russia. The United Nations-led COVAX initiative provided Oxford/AstraZeneca and Pfizer/BioNTech doses to several African countries. Within this program, the continent received nearly 270 million doses as of January 2022. Moreover, the vaccination campaign has also been an occasion for intra-African solidarity. Senegal has, for instance, donated vaccines to the Gambia, while in January 2021, Algeria announced that it would have shared its supply with Tunisia.

COVID-19 impact on the African economy

The spread of COVID-19 negatively affected socio-economic growth in Africa, with the continent’s Gross Domestic Product (GDP) contracting significantly in 2020. Specifically, Southern Africa experienced the sharpest decline, at minus six percent, followed by North Africa at minus 1.7 percent. Most of Africa’s key economic sectors were hit by the pandemic. The drop in global oil prices led to a crisis in the oil and gas sector. Nigeria, the continent’s leading oil-exporting country, witnessed a considerable decrease in crude oil trade in 2020. Moreover, the shrinking number of international tourist arrivals determined a loss of over 12 million jobs in Africa’s travel and tourism sector. Society has also been substantially affected by COVID-19 on the poorest continent in the world, and the number of people living in extreme poverty was estimated to increase by around 30 million in 2020.

Immunization, measles (% of children ages 12-23 months) in Russia was reported at 97 % in 2023, according to the World Bank collection of development indicators, compiled from officially recognized sources. Russia - Immunization, measles (% of children ages 12-23 months) - actual values, historical data, forecasts and projections were sourced from the World Bank on March of 2025.

February 2nd Update

The AP has requested a timeseries dataset reporting daily counts for distributed and administered vaccines in the U.S. from the CDC. In the absence of that dataset, we are storing daily snapshots of the cumulative counts provided by the CDC COVID Data Tracker and compiling a timeseries dataset here. This process has captured cumulative counts going back to January 4th and daily counts of new doses administered and distributed going back to January 5th. The timeseries dataset also includes seven-day rolling average calculations for the daily metrics.

We have identified a few instances of decreasing cumulative counts in this timeseries, which result in single-day negative counts. We are treating these instances as corrections, and include the negative counts in the rolling averages.

We are investigating the cumulative count decreases and will update the timeseries dataset if necessary with additional information from the CDC. When the CDC provides its own timeseries dataset we will make that available here.

Overview

The AP is using data provided by the Centers for Disease Control and Prevention to report vaccine doses distributed and administered in the United States.

This data is from the CDC's COVID Data Tracker, which is updated daily. However, keep in mind that healthcare providers can report doses to federal, state, territorial, and local agencies up to 72 hours after doses are administered.

To learn more about AP's data journalism capabilities for publishers, corporations and financial institutions, go here or email kromano@ap.org.

Interactive

The AP has designed an interactive map to track COVID-19 vaccine counts reported by The CDC. @(https://interactives.ap.org/embeds/TUVpf/14/)

Interactive Embed Code

<iframe title="Tracking US COVID vaccinations" aria-label="Map" id="datawrapper-chart-TUVpf" src="https://interactives.ap.org/embeds/TUVpf/14/" scrolling="no" width="100%" style="border:none" height="548"></iframe><script type="text/javascript">!function(){"use strict";window.addEventListener("message",(function(a){if(void 0!==a.data["datawrapper-height"])for(var e in a.data["datawrapper-height"]){var t=document.getElementById("datawrapper-chart-"+e)||document.querySelector("iframe[src*='"+e+"']");t&&(t.style.height=a.data["datawrapper-height"][e]+"px")}}))}();</script>

Caveats

From The CDC: - Numbers reported on CDC’s website are validated through a submission process with each jurisdiction and may differ from numbers posted on other websites. - Differences between reporting jurisdictions and CDC’s website may occur due to the timing of reporting and website updates. - The process used for reporting doses distributed or people vaccinated displayed by other websites may differ.

Market Overview:

The United States vaccines market size is projected to exhibit a growth rate (CAGR) of 5.91% during 2024-2032. The regulatory support and approval processes, the emerging infectious diseases, the rise of telehealth and remote healthcare services, the favorable healthcare policies, and the international collaborations and partnerships are some of the factors propelling the market.

Vaccines are biological substances designed to stimulate the immune system to recognize and fight specific pathogens, such as viruses or bacteria. They play a crucial role in preventing infectious diseases and promoting public health. Vaccines are typically composed of weakened or inactivated forms of the targeted microorganism or specific components, such as proteins or genetic material. When administered, vaccines prompt the immune system to produce an immune response, including the production of antibodies and the development of immune memory. This immune memory allows the body to recognize and rapidly respond to the actual pathogen if encountered in the future, providing protection against infection and often preventing the onset of diseases. Vaccination programs have been instrumental in controlling and eradicating infectious diseases globally. Common vaccines include those for measles, mumps, rubella, polio, influenza, hepatitis, and more. In addition to individual protection, vaccines contribute to herd immunity, reducing the overall spread of infectious agents within communities. Continuous research and advancements in vaccine technology, such as mRNA vaccines, have expanded the scope and efficacy of vaccination efforts. Vaccines have been pivotal in controlling pandemics, as evidenced by their role in combating diseases like smallpox and, more recently, in the global response to the COVID-19 pandemic. They represent a powerful tool in public health, preventing illness, reducing the burden on healthcare systems, and saving countless lives by effectively bolstering the body's immune defenses against a wide array of infectious agents.

United States Vaccines Market Trends:

The market in the United States is majorly driven by the advancements in vaccine development. In line with this, the COVID-19 pandemic has accelerated vaccine research, production, and distribution efforts. The urgency to address the global health crisis has led to increased investments, collaborations, and government support for vaccine development, contributing significantly to market growth. Furthermore, the rising awareness of the importance of vaccination in preventing infectious diseases has driven demand. Routine vaccinations for diseases like influenza, measles, mumps, rubella, and hepatitis have gained prominence as individuals and healthcare providers recognize the value of immunization in maintaining public health. Government initiatives and public health programs play a pivotal role in driving the vaccine market. Programs such as the Vaccines for Children (VFC) program, which provides vaccines to eligible children, and the Adult Immunization Initiative contribute to increased vaccine accessibility and utilization. Additionally, the emergence of innovative vaccine technologies has expanded the market. mRNA vaccine platforms, as demonstrated by the success of COVID-19 vaccines, showcase the potential for rapid development and effectiveness against a variety of pathogens. This has spurred interest and investment in novel vaccine approaches, driving market growth. The aging population in the United States is a significant factor influencing the vaccine market. As individuals age, there is a higher susceptibility to certain diseases, necessitating vaccinations to prevent complications. This demographic shift contributes to the demand for vaccines targeting conditions prevalent in older adults, such as shingles and pneumococcal diseases. Pharmaceutical companies and biotech firms are increasingly focusing on vaccine research and development. Partnerships between industry players and research institutions, along with advancements in vaccine manufacturing technologies, drive innovation and contribute to the growth of the vaccine market. Besides, the growing importance of travel vaccines, as people increasingly engage in international travel, adds to market expansion. Vaccines for diseases prevalent in different regions become essential for travelers, promoting a global market for travel-related immunizations.

United States Vaccines Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country level for 2024-2032. Our report has categorized the market based on technology, patient type, indication, route of administration, product type, treatment type, end user, and distribution channel.

Technology Insights:

https://www.imarcgroup.com/CKEditor/4df2be45-fb2f-4a09-890a-76b18e7708deother-regions1.webp" style="height:450px; width:800px" />

• Conjugate Vaccines
• Inactivated and Subunit Vaccines
• Live Attenuated Vaccines
• Recombinant Vaccines
• Toxoid Vaccines
• Others
  

The report has provided a detailed breakup and analysis of the market based on the technology. This includes conjugate vaccines, inactivated and subunit vaccines, live attenuated vaccines, recombinant vaccines, toxoid vaccines, and others.

Patient Type Insights:

• Pediatric
• Adult
  

A detailed breakup and analysis of the market based on patient type have also been provided in the report. This includes pediatric and adult.

Indication Insights:

• Bacterial Diseases
  • Meningococcal Disease
  • Pneumococcal Disease
  • Diphtheria/Tetanus/Pertussis (DPT)
  • Tuberculosis
  • Haemophilus Influenzae (Hib)
  • Typhoid
  • Others
• Viral Diseases
  • Hepatitis
  • Influenza
  • Human Papillomavirus (HPV)
  • Measles/Mumps/Rubella (MMR)
  • Rotavirus
  • Herpes Zoster
  • Varicella
  • Japanese Encephalitis
  • Rubella
  • Polio
  • Rabies
  • Dengue
  • Others
    

The report has provided a detailed breakup and analysis of the market based on the indication. This includes bacterial diseases (meningococcal disease, pneumococcal disease, diphtheria/tetanus/pertussis (DPT), tuberculosis, haemophilus influenzae (HIB), typhoid, and others) and viral diseases (hepatitis, influenza, human papillomavirus (HPV), measles/mumps/rubella (MMR), rotavirus, herpes zoster, varicella, Japanese encephalitis, rubella, polio, rabies, dengue, and others).

Route of Administration Insights:

• Intramuscular and Subcutaneous Administration
• Oral Administration
• Others
  

A detailed breakup and analysis of the market based on route of administrations have also been provided in the report. This includes intramuscular and subcutaneous administration, oral administration, and others.

Product Type Insights:

• Multivalent Vaccine
• Monovalent Vaccine
  

<p

Thailand TH: Immunization: Measles: % of Children Aged 12-23 Months data was reported at 99.000 % in 2017. This stayed constant from the previous number of 99.000 % for 2016. Thailand TH: Immunization: Measles: % of Children Aged 12-23 Months data is updated yearly, averaging 95.000 % from Dec 1984 (Median) to 2017, with 34 observations. The data reached an all-time high of 99.000 % in 2017 and a record low of 5.000 % in 1984. Thailand TH: Immunization: Measles: % of Children Aged 12-23 Months data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Thailand – Table TH.World Bank: Health Statistics. Child immunization, measles, measures the percentage of children ages 12-23 months who received the measles vaccination before 12 months or at any time before the survey. A child is considered adequately immunized against measles after receiving one dose of vaccine.; ; WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/).; Weighted average;

Immunization, DPT (% of children ages 12-23 months) in Norway was reported at 96 % in 2023, according to the World Bank collection of development indicators, compiled from officially recognized sources. Norway - Immunization, DPT (% of children ages 12-23 months) - actual values, historical data, forecasts and projections were sourced from the World Bank on March of 2025.

Immunization, BCG (% of one-year-old children) in Turkey was reported at 98 % in 2023, according to the World Bank collection of development indicators, compiled from officially recognized sources. Turkey - Immunization, BCG (% of one-year-old children) - actual values, historical data, forecasts and projections were sourced from the World Bank on March of 2025.